The efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients with acute myeloid leukemia in first relapse.

被引：0
|
作者：
Voliotis, D
Mineur, P
Dombret, H
Theobald, M
Boogaerts, M
Löwenberg, B
Sievers, EL
Larson, RA
Estey, E
Diehl, V
Stadtmauer, EA
机构：
[1] Univ Cologne, Clin Internal Med 1, Koeln, Germany
[2] Hop St Joseph, Gilly Charleroi, Belgium
[3] Hop St Louis, Paris, France
[4] Univ Clin Mainz, Mainz, Germany
[5] Univ Ziekenhuis Gasthuisberg, Louvain, Belgium
[6] Dijkzigt Ziekenhuis Rotterdam, Rotterdam, Netherlands
[7] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] Univ Penn, Philadelphia, PA 19104 USA
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
424O
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [21] Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg™ CMA-676)
    Petti, MC
    Pinazzi, MB
    Diverio, D
    Romano, A
    Petrucci, MT
    De Santis, S
    Meloni, G
    Tafuri, A
    Mandelli, F
    Lo Coco, F
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) : 63 - 65
  • [22] Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia
    Akihiro Takeshita
    International Journal of Hematology, 2013, 97 : 703 - 716
  • [23] Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia
    Takeshita, Akihiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (06) : 703 - 716
  • [24] Central nervous system and plasma gemtuzumab ozogamicin (Mylotarg™, CMA-676) levels in a patient with medullary and extra-medullary relapsed acute myeloid leukemia:: A case report.
    Weinthal, JA
    Lenarsky, C
    Goldman, S
    Leopold, LH
    Berger, MS
    Liu, HJ
    King, SP
    Korth-Bradley, J
    Dowell, JA
    BLOOD, 2000, 96 (11) : 219B - 219B
  • [25] Gemtuzumab ozogamicin in acute myeloid leukemia
    Godwin, C. D.
    Gale, R. P.
    Walter, R. B.
    LEUKEMIA, 2017, 31 (09) : 1855 - 1868
  • [26] Gemtuzumab ozogamicin for acute myeloid leukemia
    Appelbaum, Frederick R.
    Bernstein, Irwin D.
    BLOOD, 2017, 130 (22) : 2373 - 2376
  • [27] Gemtuzumab ozogamicin in acute myeloid leukemia
    C D Godwin
    R P Gale
    R B Walter
    Leukemia, 2017, 31 : 1855 - 1868
  • [28] Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia
    Abedin, Sameem M.
    Badar, Talha
    Gauger, Katelyn
    Michaelis, Laura C.
    Runaas, Lyndsey
    Carlson, Karen-Sue
    Murthy, G. S. Guru
    Atallah, Ehab
    LEUKEMIA RESEARCH, 2022, 123
  • [29] Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia
    Arceci, RJ
    Sande, J
    Lange, B
    Shannon, K
    Franklin, J
    Hutchinson, R
    Vik, TA
    Flowers, D
    Aplenc, R
    Berger, MS
    Sherman, ML
    Smith, FO
    Bernstein, I
    Sievers, EL
    BLOOD, 2005, 106 (04) : 1183 - 1188
  • [30] Licensure of Gemtuzumab Ozogamicin for the Treatment of Selected Patients 60 Years of Age or Older with Acute Myeloid Leukemia in First Relapse
    Mark S. Berger
    Lance H. Leopold
    James A. Dowell
    Joan M. Korth-Bradley
    Matthew L. Sherman
    Investigational New Drugs, 2002, 20 : 395 - 406
12345